Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 10 (7) , 1294-1308
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81725020, 81872742)
- Shanghai Municipal Education Commission (2019-01-07-00-07-E00073)
This publication has 42 references indexed in Scilit:
- Novel fluorescent probes of 10-hydroxyevodiamine: autophagy and apoptosis-inducing anticancer mechanismsActa Pharmaceutica Sinica B, 2019
- Inhibitors of histone deacetylase as antitumor agents: A critical reviewBioorganic Chemistry, 2016
- Polypharmacology – Foe or Friend?Journal of Medicinal Chemistry, 2013
- Class I HDACs Share a Common Mechanism of Regulation by Inositol PhosphatesMolecular Cell, 2013
- Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of SeparationCancer Discovery, 2012
- New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure–Activity Relationship Analysis and Biological EvaluationsJournal of Medicinal Chemistry, 2012
- The Epigenomics of CancerCell, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Strategies for optimizing combinations of molecularly targeted anticancer agentsNature Reviews Drug Discovery, 2006
- Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589Clinical Cancer Research, 2006